Covaxin’s phase-I trial participant faced adverse effect in Aug
_1594052644844_1594052732451_1605952560806.jpg)
- Earlier this week, it started its third and final stage of the clinical trial at Nizam’s Institute of Medical Sciences. The company plans to enrol up to 26,000 participants in the massive phase 3 trial, expected to cost about ₹150 crore